Stage 3 Endometrial Cancer Treatment in Ahmedabad — Dr. Nishtha Tripathi Patel is an ESGO-certified gynaecological oncosurgeon offering specialist treatment for stage 3 endometrial cancer treatment at Sterling Hospitals, KD Hospital and Welcare Speciality Hospital in Ahmedabad.
On this page
- What this stage means
- Recommended treatment pathway
- Adjuvant therapy
- Outlook and survival data
- Booking
- FAQs
Stage 3 endometrial cancer treatment — What does this stage mean?
Stage 3 endometrial cancer has spread to adnexa, vagina, parametrium, or lymph nodes. Treatment is cytoreductive surgery + chemotherapy + radiation, in sequence depending on disease distribution. Newer protocols include immunotherapy for mismatch-repair-deficient tumours.
For broader information see our cancer overview and treatment page.
Recommended treatment pathway
Stage 3 endometrial cancer has spread to adnexa, vagina, parametrium, or lymph nodes. Treatment is cytoreductive surgery + chemotherapy + radiation, in sequence depending on disease distribution. Newer protocols include immunotherapy for mismatch-repair-deficient tumours.
Adjuvant therapy
Chemotherapy (carboplatin-paclitaxel) and radiation. Pembrolizumab + lenvatinib for selected MSI-high or POLE-mutant cases.
Outlook
5-year survival 50-65% with optimal multimodality treatment; molecular subtyping increasingly guides prognosis.
External authoritative reference: NCCN Guidelines and ESGO Recommendations.
Booking
For an individualised treatment plan, share your reports on WhatsApp (+91 76988 00333) or book an appointment. Second opinions are available for patients already under care elsewhere.
FAQs
Where is stage 3 endometrial cancer treatment performed in Ahmedabad?
Dr. Nishtha Tripathi Patel treats this disease stage at Sterling Hospitals (Sindhubhavan), KD Hospital, and Welcare Speciality Hospital in Ahmedabad. The hospital is chosen based on the specific procedure needed and patient preference.
What is the typical hospital stay?
For minimally invasive surgery (robotic or laparoscopic), hospital stay is typically 3-4 days. For cytoreductive surgery or HIPEC, stay extends to 7-10 days. Chemoradiation is outpatient over 5-7 weeks.
What is the likely outcome?
5-year survival 50-65% with optimal multimodality treatment; molecular subtyping increasingly guides prognosis. Outcomes are stage-dependent and individual; the figures above are averages from published series.
Is fertility preservation possible?
Fertility preservation is not standard for this stage. Egg or embryo cryopreservation may be considered before chemotherapy if applicable.
Can I get a second opinion before deciding?
Yes. Share your reports on WhatsApp (+91 76988 00333). Dr. Nishtha provides independent review of stage, pathology, imaging and proposed treatment within 24-48 hours.
Reviewed by Dr. Nishtha Tripathi Patel, MBBS, DGO, DNB, Fellowship Gynaecological Oncology, ESGO-certified.